Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Regulation of dendritic cell maturation in osimertinib-treated lung adenocarcinoma patients.

Journal of the Formosan Medical Association = Taiwan yi zhi - 1 Sept 2023

Wu Ming-Fang, Chang Ya-Hsuan, Chen Hsuan-Yu, Ho Chao-Chi, Chen Huei-Wen

Abstract excerpt

Osimertinib (OSI), a third-generation tyrosine kinase inhibitor (TKI), efficiently benefits lung adenocarcinoma (LUAD) patients with epidermal growth factor receptor (EGFR) mutations. However, combined OSI and immune checkpoint inhibitor in EGFR-mutant patients increases the incidence of interstitial lung disease (ILD), although the mechanism is unknown. Here, we investigated the interaction between dendritic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dendritic Cells

Share to ErbB Receptors

Share to Lung Diseases, Interstitial

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 37169657
DOI: 10.1016/j.jfma.2023.04.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Regulation of dendritic cell maturation in osimertinib-treated lung adenocarcinoma patients.PMID 37169657Read ↗

Exploiting tumor-associated dendritic cell heterogeneity for novel cancer therapiesSemantic proximity Read ↗

Functional Role of Dendritic Cell Subsets in Cancer Progression and Clinical ImplicationsSemantic proximity Read ↗

Dendritic Cells and Their Role in Immunotherapy.Semantic proximity Read ↗

Dendritic Cells in the Cancer MicroenvironmentSemantic proximity Read ↗

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumorsSemantic proximity Read ↗

Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report.Semantic proximity Read ↗

TGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung Cancer.Semantic proximity Read ↗

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.Semantic proximity Read ↗

Tumor-infiltrating dendritic cells in cancer pathogenesis.Semantic proximity Read ↗

Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.Semantic proximity Read ↗

Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.Semantic proximity Read ↗

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin PathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.